MS & Immune Disorders

Filter Your Results

 

News

 

Promising Results Published for Pembrolizumab to Treat Progressive Multifocal Leukoencephalopathy

Tuesday, April 16, 2019—As published in the New England Journal of Medicine, positive results have been seen in a small study of pembrolizumab (Keytruda; Merck, Kenilworth, NJ) for treatment of …

FDA Approves Cladribine Tablets—First and Only Short-Course Treatment for Relapsing-Remitting MS

Monday, April 01, 2019—The Food and Drug Administration (FDA) has approved cladribine tablets (Mavenclad; EMD Serono, Rockland, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) and…

Siponimod Approved by FDA for Treatment of Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis

Wednesday, March 27, 2019—The first drug to treat 3 phases of multiple sclerosis (MS), secondary-progressive MS (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome (CIS), has b…

Patient’s Risk Tolerance for Disease Modifying Treatments for Multiple Sclerosis

Friday, March 15, 2019—In a study published in Neurology, researchers at the Cleveland Clinic evaluated patients’ tolerance for potential risks of multiple sclerosis (MS) medications. Stu…

Analysis of Cladribine Tablets Clinical Trials Continues to Support Safety and Efficacy

Thursday, March 07, 2019—In the 2-year CLARITY trial (NCT00213135), 47% of patients treated with cladribine tablets (CT) (EMD Serono; Rockland, MA) achieved no evidence of disease activity (NEDA) comp…

Social Networks May Be a Modifiable Risk Factor for MS Progression

Monday, March 04, 2019—Using social network surveys to identify patients with stronger vs weaker social networks (SNs), researchers found that persons with multiple sclerosis (MS) who had significan…

Positive Long-Term Efficacy and Safety of Teriflunomide

Monday, March 04, 2019—Annualized relapse rates (ARR) were significantly lowered for patients treated with 14 mg teriflunomide (Aubagio; Sanofi, Bridgewater, NJ) compared with those treated with pla…

Positive Results for Ublituximab in Phase 2 Clinical Trial

Saturday, March 02, 2019—Patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with ublituximab (TG Therapeutics, New York, NY) (n = 46) had rapid depletion of B cells, reduced …

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC